NYSE:LLY

Eli Lilly Stock News

Healthcare > Drug Manufacturers - General

Buy LLY

*Your capital is at risk

$1,125.38

+42.15 (+3.89%)

At Close: Jun 04, 2026

Eli Lilly: A Potential Game Changer For Weight Management And Cardiovascular Health

11:19pm, Wednesday, 13'th Sep 2023

Eli Lilly's stock has performed well in the market, boosted by strong fundamental results and the success of Novo Nordisk's weight loss drug, Wegovy. Wegovy demonstrated a 20% reduction in the risk of

"Blockbuster Status": 3 Bios to Buy and Hold

03:47pm, Wednesday, 13'th Sep 2023

The biotech sector is notorious for its sky-high R&D costs, regulatory hurdles, and lengthy timelines to bring a drug to market. Stock Strategist Andrew Rocco unveils 3 biotech stocks that have broken

NVS vs. LLY: Which Stock Is the Better Value Option?

12:50pm, Tuesday, 12'th Sep 2023

Investors interested in Large Cap Pharmaceuticals stocks are likely familiar with Novartis (NVS) and Eli Lilly (LLY). But which of these two stocks presents investors with the better value opportunity

Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know

10:35am, Tuesday, 12'th Sep 2023

Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Should You Still Buy the S&P 500's Best-Performing August Stocks?

05:50am, Tuesday, 12'th Sep 2023

Arista Networks stock soared 26% last month as the demand for its cloud-networking technology surged. Eli Lilly's shares jumped 22% with diabetes drug Mounjaro fueling its revenue growth.

Pound for Pound: 3 Buzzworthy Drug Stocks Worth Their Weight in Gold

09:59pm, Monday, 11'th Sep 2023

Weight-loss drugs are taking the U.S. by storm. JPMorgan Chase (NYSE: JPM ) is forecasting that the market for weight-loss medications could reach $100 billion in annual sales.

Investors May Not Have Seen the Best From Eli Lilly Stock Yet. Here's Why.

06:12am, Sunday, 10'th Sep 2023

Eli Lilly's type 2 diabetes treatment, called Mounjaro, is helping fuel new growth for the company. In addition to diabetes, Eli Lilly is looking to fast track Mounjaro for weight-loss approval by the

Analysis: Wegovy launch in UK may underline Novo's need to get ahead of Lilly

03:07am, Sunday, 10'th Sep 2023

Novo Nordisk's decision to launch its weight-loss drug Wegovy in Britain last week despite severe supply constraints may partly have been motivated by a desire to get ahead of rival Eli Lilly's own si

Big pharma's blockbuster obesity drug battle is just getting started, and it's headed for $100 billion

09:19am, Saturday, 09'th Sep 2023

As Novo Nordisk and Eli Lilly duke it out in the weight-loss drug market with Ozempic, Wegovy and Mounjaro, drug company competitors plan to join the fray.

Only 2 Mega-Cap Monster Stocks Have Risen in Each of the Last 5 Years: Are They Buys Now?

05:52am, Saturday, 09'th Sep 2023

Of the more than 40 current mega-cap stocks, only two have generated positive returns in each of the last five years. One is a highly diversified conglomerate, while the other is a fast-growing pharma

The economic cost of obesity is expected to soar to $4 trillion by 2035. Weight loss drugs like Ozempic could change that, Goldman Sachs says.

01:44pm, Friday, 08'th Sep 2023

The rise in obesity is having a massive impact on the global economy, according to Goldman Sachs. The bank estimates that obesity will drag down the world's GDP by $4 trillion in 2035.

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by